Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Aktis Oncology, Inc.

NASDAQ: AKTS · Life Sciences · 3 alerts · CIK 2035832

Share price
$16.16Close, Nov 16
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Aktis Oncology, Inc. filings on SEC EDGAR ↗

8:09 AM ET 10-Q
Financial Results

Aktis Oncology Q3 2026 Results: Net Loss of $29.9M, Loss Widens

Aktis Oncology reported a net loss of $72.4 million for the nine months ended September 30, 2026, compared to $48.6 million in the prior year, driven by increased R&D and G&A expenses. The company significantly strengthened its balance sheet during the period through an initial public offering and the conversion of preferred stock, ending the quarter with $492.9 million in cash and marketable securities.

Key figure
Net loss $29.9M
8:05 AM ET 8-K
Financial Results

Aktis Oncology Financial Results

Aktis Oncology reported financial results for the third quarter of 2026, highlighting the initiation of its third Phase 1b clinical trial (BActinium-2) for AKY-2519. The company also operationalized its in-house GMP manufacturing facility in Boston and remains on track to present preliminary clinical data for its lead programs in 2027.

Term
Q3 2026

“Aktis is on a trajectory to redefine radiopharmaceuticals as a major pillar of cancer treatment by expanding the modality to more targets, broader indications, and larger patient populations. In the third quarter, we continued to make tremendous progress operationalizing this vision.”

Matthew Roden, Ph.D., President and Chief Executive Officer

“With the initiation of the BActinium-2 trial of AKY-2519, we now have three clinical trials underway in the U.S. across two novel targets, Nectin-4 and B7-H3, which are both implicated in a range of solid tumor types. We also opened the first backfill cohorts in our ongoing NECTINIUM-2 and BActinium-1 trials to further characterize safety and preliminary antitumor activity at the selected doses, while dose escalation continues in both studies.”

Matthew Roden, Ph.D., President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.